Share this video  

ASCO 2017 | The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers

Howard Burris • 2 Jun 2017
ASCO 2017

Howard A. Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN discusses the TRK inhibitor LOXO-101 (larotrectinib) and its impact on patients with TRK fusion cancers (NCT02576431, NCT02122913, NCT02637687). Dr Burris emphasizes that this highlights the importance of looking at the molecular profile of patients.
This interview was recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

More from Howard Burris

1:22
The importance of knowing the molecular profile of a patient's tumor
Howard Burris • 2 Jun 2017
2:14
New potential applications for CAR T-cell therapy
Howard Burris • 1 Jun 2018
1:06
An evaluation of the ICONIC study: JTX-2011 in combination with nivolumab
Howard Burris • 1 Jun 2017
1:09
Results of the combined inhibition of IDO1 and PD-L1 in locally advanced or metastatic solid tumors
Howard Burris • 2 Jun 2017
The content of VJOncology is intended for healthcare professionals